TRVI Stock Forecast & Price Target

Trevi Therapeutics Inc. has achieved an optimistic outlook due to increased projected sales for Haduvio across various indications, supported by strong data reflecting low-dose and rapid efficacy. The RIVER RCC trial demonstrated significant improvement in responder rates, complementing supportive patient-reported outcomes and showcasing an absence of new safety concerns. Consequently, the company has revised its peak sales projections for Haduvio to $1.7 billion, indicating confidence in market penetration and pricing strategies, alongside potential international revenue and further value from additional indications.

Trevi Therapeutics Inc. faces significant financial challenges, including increasing operating expenses associated with the ongoing clinical development of Haduvio, which may lead to substantial losses and cash burn until the projected product launch in 2029. The company's discounted cash flow (DCF) analysis suggests a terminal decline of 7% starting in 2035, indicating potential concerns about the sustainability of Haduvio's market position following its peak around 2038. Additionally, comparative studies reveal that Trevi's investigational therapy may be less efficacious relative to competitors, raising further doubts about its ability to capture market share and generate sufficient revenue.